Findings on Synthetic Hypericin in Cutaneous T-Cell Lymphoma

Key Takeaways:

• In cutaneous T-cell lymphoma, synthetic hypericin was reported to show higher 12-week treatment success and greater cumulative mCAILS improvement than mechlorethamine.
• The authors said the difference was not statistically significant, citing both small sample size and more extensive disease in the synthetic hypericin arm.

60% of synthetic hypericin-treated patients met the prespecified treatment-success threshold at 12 weeks, compared with 20% of those treated with mechlorethamine. Treatment success was defined prospectively as at least 50% improvement in cumulative mCAILS compared with baseline. The authors also note average cumulative mCAILS improvement of 52.5% with synthetic hypericin and 34.7% with mechlorethamine over the same period. These assessments were based on 3-5 prospectively identified index lesions per patient.

The authors attributed the lack of statistical significance to the small sample and noted an imbalance after randomization, with the synthetic hypericin group including patients with more extensive disease. The findings were consistent with prior studies suggesting rapid onset of action and a favorable safety profile, while also noting that the sample size limited statistical certainty.

Synthetic hypericin was well tolerated in all patients during the comparative treatment period. In the mechlorethamine group, local findings included rash, application-site sensitivity, allergic contact dermatitis, and dermatitis. The team recorded one temporary treatment interruption, one permanent discontinuation, and one withdrawal linked to these local events in the mechlorethamine group.